158 related articles for article (PubMed ID: 24870877)
1. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM).
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):15-7. PubMed ID: 24870877
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Anderlini P; Saliba RM; Ledesma C; Plair T; Alousi AM; Hosing CM; Khouri IF; Nieto Y; Popat UR; Shpall EJ; Fanale MA; Hagemeister FB; Oki Y; Neelapu S; Romaguera JE; Younes A; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1333-1337. PubMed ID: 27064056
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Walewski J; Hellmann A; Siritanaratkul N; Ozsan GH; Ozcan M; Chuncharunee S; Goh AS; Jurczak W; Koren J; Paszkiewicz-Kozik E; Wang B; Singh S; Huebner D; Engert A; von Tresckow B
Br J Haematol; 2018 Nov; 183(3):400-410. PubMed ID: 30168134
[TBL] [Abstract][Full Text] [Related]
7. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Deau B; Amorim S; Perrot A; Quittet P; Cornillon J; Chaoui D; Marolleau JP; Oberic L; Le Du K; Fornecker LM; Tournilhac O; Veillard AS; Chaillol I; Robin M; Tamburini J; Brice P
Br J Haematol; 2018 May; 181(3):341-349. PubMed ID: 29611187
[TBL] [Abstract][Full Text] [Related]
8. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Castagna L; Garnier F; Guillaume T; Socié G; Maury S; Maillard N; Tabrizi R; Marchand T; Malfuson J; Gac A; Gyan E; Mercier M; Béguin Y; Delage J; Turlure P; Marçais A; Nguyen S; Dulery R; Bay J; Huynh A; Daguindau E; Cornillon J; Régny C; Michallet M; Peffault de Latour R; Yakoub-Agha I; Blaise D
Bone Marrow Transplant; 2017 May; 52(5):689-696. PubMed ID: 28067872
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
12. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
[TBL] [Abstract][Full Text] [Related]
13. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):7. PubMed ID: 24870873
[No Abstract] [Full Text] [Related]
15. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Palmer JM; Thomas SH; Tsai NC; Farol L; Nademanee A; Forman SJ; Gopal AK
Blood; 2012 Jun; 119(26):6379-81. PubMed ID: 22611160
[TBL] [Abstract][Full Text] [Related]
16. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era.
Hegerova L; Cao Q; Lazaryan A; McClune BL; Weisdorf DJ; Brunstein CG; Bachanova V
Bone Marrow Transplant; 2017 May; 52(5):697-703. PubMed ID: 28134921
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P; Kim HT; Ho VT; Cutler CS; Koreth J; Antin JH; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2008 Apr; 14(4):418-25. PubMed ID: 18342784
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.
Sasse S; Rothe A; Goergen H; Eichenauer DA; Lohri A; Kreher S; Jäger U; Bangard C; Kuhnert G; Böll B; von Tresckow B; Engert A
Leuk Lymphoma; 2013 Oct; 54(10):2144-8. PubMed ID: 23402268
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE
Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
